Therapeutic Drug Monitoring (TDM) with different tolerable doses of memantine for cognitive function preservation in Indian patients with brain metastasis treated with radiation. - NIL

Start Date01 May 2025

Sponsor / Collaborator-

NCT06594172 / Not yet recruitingPhase 2IIT

A Phase II Clinical Trial of of Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy

This clinical trial aims to evaluate the efficacy of early intervention with Memantine and Pioglitazone in preventing Radiation-Induced Brain Injury (RIBI) in patients undergoing cranial radiotherapy.
RIBI, a significant complication of radiation therapy for primary and metastatic brain tumors, as well as head and neck cancers, often presents with delayed and irreversible neurological damage, severely affecting patients' quality of life.
Our previous studies have indicated that Memantine, an NMDAR antagonist, and Pioglitazone, a PPAR-γ agonist, play crucial roles in modulating the neuroprotective immune microenvironment by targeting key mechanisms of neuron-astrocyte fatty acid metabolism coupling. These findings suggest that early administration of these drugs could protect cognitive function and reduce neuroinflammation in patients post-radiation.
This prospective phase II clinical trial will assess the combined efficacy of Memantine and Pioglitazone in improving cognitive outcomes and preventing RIBI without adversely impacting the anti-tumor efficacy of radiation therapy. The study will also explore the synergistic effects of these two FDA-approved drugs in early-stage RIBI prevention, providing a new therapeutic strategy for enhancing the quality of life in cancer patients receiving radiotherapy.

Start Date10 Sep 2024

Sponsor / Collaborator

Guangdong Provincial People's Hospital

[+2]

CTRI/2024/07/069806 / Not yet recruitingNot ApplicableIIT

To study Memantine as an add-on drug to Escitalopram for Geriatric depression: A double-blind trial - NIL

Start Date12 Jul 2024

Sponsor / Collaborator

Dayanand Medical College & Hospital

100 Clinical Results associated with Memantine hydrochloride

100 Translational Medicine associated with Memantine hydrochloride

100 Patents (Medical) associated with Memantine hydrochloride

205

Literatures (Medical) associated with Memantine hydrochloride

01 Feb 2025·Pharmaceutical nanotechnology

Optimizing Neuroprotective Nano-structured Lipid Carriers for Transdermal Delivery through Artificial Neural Network

Article

Author: Prajapati, Bhupendra ; Dalwadi, Saloni ; Thakkar, Vaishali

Background::

Dementia associated with Alzheimer’s disease (AD) is a neurological disorder. AD is a progressive neurodegenerative condition that predominantly impacts the elderly population, although it can also manifest in younger people through the impairment of cognitive functions, such as memory, cognition, and behaviour. Donepezil HCl and Memantine HCl are encapsulated in Nanostructured Lipid Carriers (NLCs) to prolong systemic circulation and minimize the systemic side effects.

Objective::

This work explores the use of data mining tools to optimize the formulation of NLCs comprising of Donepezil HCl and Memantine HCl for transdermal drug delivery. Neuroprotective drugs and excipients are utilized for protecting the nervous system against damage or degeneration.

Method::

The NLCs were formulated using a high-speed homogenization technique followed by ultrasonication. NLCs were optimized using Box Behnken Design (BBD) in Design Expert Software and artificial neural network (ANN) in IBM SPSS statistics. The independent variables included the ratio of solid lipid to liquid lipid, the percentage of surfactant, and the revolutions per minute (RPM) of the high-speed homogenizer.

Results::

The NLCs that were formulated had a mean particle size ranging from 67.0±0.45 to 142.4±0.52 nm. Both drugs have a %EE range over 75%, and Zeta potential was determined to be - 26±0.36 mV. CryoSEM was used to do the structural study. The permeation study showed the prolonged release of the formulation.

Conclusion::

The results indicate that NLCs have the potential to be a carrier for transporting medications to deeper layers of the skin and reaching systemic circulation, making them a suitable formulation for the management of Dementia. Both ANN and BBD techniques are effective tools for systematically developing and optimizing NLC formulation.

01 Aug 2024·BIOMEDICINE & PHARMACOTHERAPY

Mitigating radiation-induced brain injury via NLRP3/NLRC4/Caspase-1 pyroptosis pathway: Efficacy of memantine and hydrogen-rich water

Article

Author: Luo, Hao ; Liu, Huan ; Xu, Kai ; Wang, Yuhao ; Lu, Xiaoyu ; Liu, Mengya ; Wang, Yong ; Qin, Xiujun ; Sun, Ge

Radiation-induced brain injury (RIBI) is a significant challenge in radiotherapy for head and neck tumors, impacting patients' quality of life. In exploring potential treatments, this study focuses on memantine hydrochloride and hydrogen-rich water, hypothesized to mitigate RIBI through inhibiting the NLRP3/NLRC4/Caspase-1 pathway. In a controlled study involving 40 Sprague-Dawley rats, divided into five groups including a control and various treatment groups, we assessed the effects of these treatments on RIBI. Post-irradiation, all irradiated groups displayed symptoms like weight loss and salivation, with notable variations among different treatment approaches. Particularly, hydrogen-rich water showed a promising reduction in these symptoms. Histopathological analysis indicated substantial hippocampal damage in the radiation-only group, while the groups receiving memantine and/or hydrogen-rich water exhibited significant mitigation of such damage. Molecular studies, revealed a decrease in oxidative stress markers and an attenuated inflammatory response in the treatment groups. Immunohistochemistry further confirmed these molecular changes, suggesting the effectiveness of these agents. Echoing recent scientific inquiries into the protective roles of specific compounds against radiation-induced damages, our study adds to the growing body of evidence on the potential of memantine and hydrogen-rich water as novel therapeutic strategies for RIBI.

01 Feb 2024·Analytical science advances

Screening stabilisers for cyanoenone triterpenoid TX101 in rat plasma samples by simultaneous analysis of parent drug and the epoxidation product

Article

Author: Tian, Lynn ; Tamer, Edward ; Tian, Qingguo

Abstract:

In the development of bioanalytical methods, stabilizing drug molecules in biological matrices is crucial for ensuring reliable exposure data in pharmacokinetic and toxicokinetic sample analyses. This study focuses on the evaluation of stabilizing effects on the synthetic triterpenoid TX101, a cyanoenone triterpenoid Nrf2 activator with known instability in plasma samples. The molecule's unsaturated double bond is susceptible to oxidation, either nonenzymatically via oxygen or enzymatically through cytochrome P450 enzyme‐catalyzed epoxidation. The research explores the impact of antioxidants (L‐ascorbic acid, sodium metabisulfite, sodium sulfite) and P450 enzyme inhibitors (sodium diethyldithiocarbamate, memantine hydrochloride, 1‐aminobenzotriazole) on TX101 stability in rat plasma samples. Results reveal that adding 2.5 mg/mL sodium sulfite or sodium metabisulfite effectively inhibits the nonenzymatic oxidation of TX101 to TX101‐epoxide, while L‐ascorbic acid shows minimal stabilizing effect. Among P450 enzyme inhibitors, sodium diethyldithiocarbamate and memantine hydrochloride exhibit modest stabilizing effects, likely attributed to their antioxidant activity. The developed High‐formance liquid chromatography coupled to tandem mass spectrometry (LC–MS/MS) method, incorporating Supported Liquid Extraction for sample cleanup, allows simultaneous monitoring of TX101 and TX101‐epoxide. Application of this method in a rat dose‐range finding study confirms successful inhibition of TX101‐epoxide formation in samples treated with sodium sulfite or sodium metabisulfite. Overall, the study emphasizes the importance of stabilizers in preventing nonenzymatic oxidation reactions during sample storage, providing valuable insights for bioanalytical method development and validation.

News (Medical) associated with Memantine hydrochloride

30 Jul 2024

·www.businesswire.com

New Study Describes a Functional, Aged, Human Cell-Based Platform That Examines the Contribution of Senescence in Alzheimer’s Disease Progression, and Response to Therapeutics

ORLANDO, Fla.--( BUSINESS WIRE )--Researchers from Hesperos and the University of Central Florida have developed a groundbreaking model using human induced pluripotent stem cell (iPSC)-derived cortical neurons to better understand and combat Alzheimer’s disease (AD). Their study, “ A functional aged human iPSC-cortical neuron model recapitulates Alzheimer’s disease, senescence, and the response to therapeutics ," has been published in the prestigious journal Alzheimer's & Dementia ® : The Journal of the Alzheimer's Association. doi.org/10.1002/alz.14044 AD affects an estimated 6.2 million Americans aged 65 and older, with projections suggesting this number could reach 14 million by 2050. Current treatments, such as acetylcholinesterase inhibitors and NMDA receptor antagonists, provide only temporary relief. The high failure rate of AD clinical trials highlights the need for a better understanding of the pathophysiology and drug mechanisms. The study addresses a critical challenge in Alzheimer’s research: the degeneration of cortical layers associated with cognitive decline. Despite substantial efforts to date, few current AD therapies are not disease-modifying. The team accurately reproduced key biological aspects of aging and senescence in a multi-cellular microphysiological system (MPS), also known as a Human-on-a-Chip. This new approach reveals how cellular aging, also known as senescence, contributes to disease progression and therapy resistance, providing researchers with an accurate, human platform to further understand the disease and potential therapeutics in a living context. Further, since other platforms at Hesperos, based on neurodegenerative diseases, have been accepted by the Food and Drug Administration (FDA) for efficacy data, it provides a new method to accelerate development and regulatory submissions of new treatments. This model provides an invaluable tool for real-time measurement of neuronal activity and aging biomarkers, facilitating drug screening and the development of AD therapies. It also reveals complex disease mechanisms, such as the role of inflammatory factors in neuronal senescence and how it differs from non-disease age-related controls, offering new targets for intervention. Researchers cultured human iPSC-derived cortical neurons on patterned microelectrode arrays to measure long-term potentiation (LTP) noninvasively. LTP, a quantifiable metric for learning and memory, is directly impacted by central nervous system neurodegeneration. By treating these neurons with pathogenic amyloid-β (Aβ), a peptide that plays a central role in development of AD, to mimic disease pathophysiology, the team was able to analyze senescence and therapeutic responses. The study demonstrates that this novel human iPSC-cortical neuron model of aging, cultured in serum-free, defined conditions, accurately recapitulates hallmarks of AD showing the following: Pathological Insights : Aβ42 induced synaptic damage, accelerated neuronal senescence, impaired mitochondrial potential, and increased reactive oxygen species (ROS), leading to oxidative stress and inflammation. Therapeutic Responses : Drugs such as memantine, rolipram, saracatinib, and donepezil improved neuronal function and viability, though they did not completely halt Aβ42-driven senescence. The study underscores the potential of biomimetic MPS systems in translational research. By integrating clinically relevant neuronal function with proteome responses, this platform is poised to accelerate the discovery of novel neuroprotective compounds for AD and other neurological disorders. “This marks a significant step forward in Alzheimer's research by providing a deeper understanding of AD pathophysiology in a human aged MPS platform. We are excited about the potential of this model to transform drug discovery in AD, providing hope for patients,” said J. Hickman, PhD, co-founder and Chief Scientist of Hesperos and Professor of Chemistry at UCF. This research was supported by grants from the National Institutes of Health (R44TR001326, R44AG058330). Research Article : doi.org/10.1002/alz.14044 Nanoscience Technology Center (NSTC) at the University of Central Florida (UCF) The mission of the NSTC is to establish a cutting-edge research program in materials and nanotechnology, provide high quality training for students and facilitate the advance of innovations to solve real world technology challenges. https://nanoscience.ucf.edu/ Hesperos, Inc. Hesperos is a global contract research organization (CRO) providing drug development services using its Human-on-a-Chip ® platform - the most advanced, multi-organ microphysiological systems available today. https://hesperosinc.com

30 Jul 2024

·www.pharmamanufacturing.com

FDA approves Alpha Cognition oral Alzheimer's treatment

The FDA has approved Alpha Cognition’s Zunveyl (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease. Zunveyl is designed to minimize gastrointestinal absorption, potentially reducing side effects common with existing Alzheimer's medications.The medication is a prodrug of galantamine , first approved in 2001, and enhances cognitive and global function by preventing the breakdown of acetylcholine and potentiating specific receptors. A prodrug is developed by attaching a small side chain to the side of the molecule so that you improve the pharmacokinetics and absorption. Once taken, the side chain falls off in the body, allowing the original main molecule to exert its therapeutic effect. The method can help the drug work better, reduce side effects, improve how it's absorbed and processed, or target specific areas in the body more effectively. Clinical studies indicate lower incidences of gastrointestinal side effects and no reported cases of insomnia, addressing key issues that often lead to medication discontinuation. This approval marks only the second oral Alzheimer's drug approved in over a decade. Last year, the FDA expanded approval to Otsuka's Rexulti (brexpiprazole) for the treatment of agitation associated with dementia due to Alzheimer’s disease. Vancouver-based Alpha Cognition is also developing Zunveyl in combination with memantine for moderate-to-severe Alzheimer's and as an intranasal formulation for cognitive impairment with mild traumatic brain injury.

Drug Approval

29 Jul 2024

·pipelinereview.com

Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease

The Second Oral Therapy Approved This Decade, ZUNVEYL’s Dual MOA Was Designed to Eliminate Drug Absorption in the Gastrointestinal (GI) Tract, Potentially Addressing Certain Tolerability Issues with Leading Alzheimer’s Disease (AD) Medications, Combined with a Long-Term Efficacy Profile ZUNVEYL’s Innovative Approach Targets AD Symptoms Directly, Designed to Provide Patients with Significant Benefits to Cognitive and Global Function and the Ability to Perform Daily Living Activities Alzheimer’s Disease, the Most Common Form of Dementia, Affects Nearly 7 Million People in the United States, including 70% of All Nursing Home Residents and is the Leading Cause of Nursing Home Admissions and Deaths VANCOUVER, Canada & DALLAS. TX, USA I July 29, 2024 I Alpha Cognition (CSE: ACOG) (OTCQB: ACOGF)(Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, announces that the U.S. Food and Drug Administration (FDA) has granted approval for ZUNVEYL® (benzgalantamine) previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer’s disease. Alzheimer’s disease (AD) is a progressive brain disorder that slowly destroys memory, thinking skills, and eventually the ability to do simple tasks, like carry on a conversation.AD is the most common form of dementia affecting nearly 7 million people, and is the leading cause of nursing home admissions and deaths, with 70% of all nursing home residents suffering with AD. A novel oral therapy, ZUNVEYL has a dual mechanism of action designed to eliminate drug absorption in the GI tract, potentiallyaddressing certain tolerability issues with leading AD medications, combined with the efficacy and long-term benefit profile of galantamine. Tolerability affects therapy adherence, with data showing that 55% of AD patients discontinue their medication after one year, mainly due to GI side effects and insomnia. Medication discontinuation can cause risk to patients themselves, and dissatisfaction and burden among nursing home staff, physicians, and caregivers. ZUNVEYL, a prodrug of AD treatment galantamine and an acetylcholinesterase inhibitor (AChEI), is postulated to exert its therapeutic effect by preventing the breakdown of acetylcholine, the important brain neurotransmitter involved in memory, motivation, and attention functions. It is also an allosteric potentiator of α-7 nicotinic acetylcholine and α4β2 receptors. This action facilitates the release of acetylcholine from the presynaptic neurons, giving clinical significance to its dual mode of action. ZUNVEYL targets AD symptoms, to provide patients with long-lasting benefits to cognitive and global function and the ability to perform daily activities that are impaired by AD. Galantamine, FDA-approved since 2001, has extensive and positive data related to long-term outcomes, demonstrating activity among multiple brain receptors, anti-inflammatory effects, and is associated with improved memory, attention, and a significantly lower risk of death. It also has the strongest effect on cognitive decline in the AChEI class of medications and demonstrated significant risk reduction of developing severe dementia. Due to its prodrug properties, ZUNVEYL is effectively converted into the active moiety of galantamine after it passes through the GI tract, therefore achieving the same therapeutic effects of galantamine. It was also uniquely designedto eliminate drug absorption in the GI tract, potentially addressing certain tolerability issues and has a CNS safety profile that includes no incidence of insomnia. Information about ZUNVEYL’s pivotal clinical studies are included further in this press release, and in the ZUNVEYL prescribing information. “I am very excited about the approval of ZUNVEYL, which we believe offers better tolerability for patients with Alzheimer’s disease. We have always believed in the efficacy of galantamine but have been limited in its use due to tolerability issues. To now have an agent with the efficacy of galantamine, but that also offers the hope of better tolerability, will provide physicians a great option to treat patients,” said Elaine Peskind, MD, the Friends of Alzheimer’s Research Professor of Psychiatry at the University of Washington School of Medicine. “This advancement marks a meaningful step forward in improving the quality of life for those living with Alzheimer’s and their families. As a geriatric psychiatrist specializing in Alzheimer’s disease, I am eager to incorporate this new treatment into our practice and see the positive difference it will make.” “The approval of ZUNVEYL is a pivotal moment in the fight against Alzheimer’s disease as it is only the second oral AD treatment to be approved in more than a decade. ZUNVEYL was designed to addresses a critical need for a tolerable and effective treatment that can potentially enhance patients’ daily lives with improved long-term outcomes,” stated Alpha Cognition Chief Executive Officer Michael McFadden. “We are delighted, as this represents a major breakthrough in Alzheimer’s treatment, providing hope to millions of patients, families, and caregivers affected by this devastating disease.” About the Pivotal ZUNVEYL Clinical Studies ZUNVEYL’s approval was based on chemistry, manufacturing, and controls information and data demonstrating the bioequivalence and tolerability of ZUNVEYL compared to galantamine immediate-release tablets and galantamine extended-release capsules. Importantly, there were minimal adverse events reported in these trials. Availability ZUNVEYL will be available by prescription in pharmacies nationwide in Q1 2025. Alpha Cognition is committed to ensuring broad access to this innovative treatment and will work closely with healthcare providers, insurers, and patient advocacy groups to support its distribution. “We are excited to launch ZUNVEYL and bring this much-needed treatment option to patients suffering from Alzheimer’s disease,” said Lauren D’Angelo, Alpha Cognition’s Chief Operating Officer. “Over the coming months, our team will work diligently to prepare for this launch, ensuring that healthcare providers have the information and patients have the resources and support they need. ZUNVEYL offers dual-action benefits with the established efficacy of galantamine and no insomnia. It was uniquely designed to bypass the gut with the potential of minimizing GI side effects. We believe that ZUNVEYL’s unique combination of these attributes will make a meaningful difference in the lives of those affected by this debilitating disease. We look forward to collaborating with our partners to ensure a successful rollout and broad accessibility.” About Alpha Cognition Inc. Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL, previously ALPHA-1062, is a novel patented oral Alzheimer’s disease therapy with a dual mechanism of action designed to eliminate drug absorption in the GI tract, potentially addressing certain tolerability issues with leading AD medications, combined with the efficacy and long-term benefit profile of galantamine. As a new generation acetylcholinesterase inhibitor, it was developed to demonstrate a potentially improved GI side effect profile and has a CNS safety profile that includes no incidence of insomnia. While precise mechanism of action is not known, it is believed that ZUNVEYL works through two distinct pathways to enhance neurotransmitter activity and protect neuronal health, leading to improved cognitive and functional outcomes. Separately, ZUNVEYL is also being developed in combination with memantine to treat moderate-to-severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. For more information about ZUNVEYL, please visit www.zunveyl.com or contact info@alphacognition.com and connect with us on Twitter and LinkedIn . INDICATION ZUNVEYL (benzgalantamine) is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. IMPORTANT SAFETY INFORMATION INDICATION ZUNVEYL® (benzgalantamine) is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. IMPORTANT SAFETY INFORMATION Contraindications ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or any inactive ingredients in ZUNVEYL. Warnings and Precautions Adverse Reactions The most common adverse reactions with galantamine tablets (≥5%) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite. Drug Interactions Cholinesterase inhibitors, including galantamine, have the potential to interfere with the activity of anticholinergic medications. A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists such as bethanechol. These are not all of the possible side effects of ZUNVEYL. You can report side effects to the FDA. Visit www.fda.gov/MedWatch or call 1‑800‑FDA‑1088. Please click here for Full Prescribing Information . SOURCE: Alpha Cognition

Drug Approval

100 Deals associated with Memantine hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D04905	Memantine hydrochloride	N06DX01	DB01043

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Alzheimer Disease	EU	H. Lundbeck A/S	15 May 2002
Alzheimer Disease	IS	H. Lundbeck A/S	15 May 2002
Alzheimer Disease	LI	H. Lundbeck A/S	15 May 2002
Alzheimer Disease	NO	H. Lundbeck A/S	15 May 2002
Dementia	DE	H. Lundbeck A/S	11 Aug 2000

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dementia, Vascular	Phase 3	RU	Merz Pharmaceuticals GmbH	23 Jan 2018
Frontotemporal Dementia	Phase 3	CA	H. Lundbeck A/S	01 Oct 2007
RRMS	Phase 3	FR	H. Lundbeck A/S	01 Sep 2005
Dementia due to Alzheimer's disease (disorder)	Phase 3	US	Forest Laboratories LLC	01 Jun 2005
Dementia due to Alzheimer's disease (disorder)	Phase 3	AR	Forest Laboratories LLC	01 Jun 2005
Dementia due to Alzheimer's disease (disorder)	Phase 3	CL	Forest Laboratories LLC	01 Jun 2005
Dementia due to Alzheimer's disease (disorder)	Phase 3	MX	Forest Laboratories LLC	01 Jun 2005
Agitation	Phase 3	US	Forest Laboratories LLC	01 Sep 2004
Cognitive Dysfunction	Phase 3	US	Forest Laboratories, Inc.	01 Apr 2004
Multiple Sclerosis	Phase 3	US	Forest Laboratories, Inc.	01 Apr 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04792645 (CTgov)	Phase 2	Trichotillomania \| Skin Diseases	100	Placebo (Placebo)	qknypysgnz(vacutmgjcv) = mjdvznrowy cdawjiyhim (lvmbuxogwc, scehzblvfy - nohljglmml) View more	-	01 Aug 2023
				Memantine (Memantine)	qknypysgnz(vacutmgjcv) = fmbemlhuam cdawjiyhim (lvmbuxogwc, nspqxceagy - caymsugjit) View more
NCT04698525 (CTgov)	Phase 3	Migraine Disorders	33	Valproate Sodium (Valproate Group)	otggtyuyfp(nxsczcowea) = yyqdfiishp aynrqvgqxo (brtsbxdeii, dqouuankac - czcyildvlc) View more	-	17 May 2023
				memantine (Memantine)	otggtyuyfp(nxsczcowea) = shzwletkwp aynrqvgqxo (brtsbxdeii, zlrkwhkuhu - cefiypytrd) View more
NCT03860597 (CTgov)	Phase 4	Schizoaffective disorder \| Schizophrenia	42	Placebo+Memantine (Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine)	xqtyupmjcu(poqjjtwtra) = ubrkehwofx rxpuiykdar (nihottqrpw, bamjsikmgc - hlpxvvlyhd) View more	-	21 Dec 2022
				Placebo+Memantine (Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo)	xqtyupmjcu(poqjjtwtra) = dvglsywzbq rxpuiykdar (nihottqrpw, nqazzyzrgk - zfpabfofgy) View more
NCT00646204 (CTgov)	Phase 4	Parkinson Disease	40	Memantine-1 (Memantine-1)	uirydozvlv(lqkblajhos) = yovgzqjjfz bujtdgzlvv (aywrhbceme, kahaqtmprj - vfjttuqngi) View more	-	13 Dec 2022
				Placebo (Placebo-2)	uirydozvlv(lqkblajhos) = uestutjuye bujtdgzlvv (aywrhbceme, abjykhjctb - cdpchxvpuu) View more
NCT02118727 (TAME, CTgov)	Phase 2	Frontotemporal Dementia \| Amyotrophic Lateral Sclerosis	89	Memantine (Memantine)	ojbkqhpqxo(kgwauvamgn) = ihqwbtzgcz lzeizszkah (psgvdkdlyj, weuepgoyur - bqrwgifxcl) View more	-	29 Nov 2022
				Placebo (for Memantine) (Placebo)	ojbkqhpqxo(kgwauvamgn) = gazgjqxfdx lzeizszkah (psgvdkdlyj, kctwsznhle - jbaesnzssa) View more
NCT04033419 (ASCO2022) Manual	Phase 2	Early Stage Breast Carcinoma	56	memantine	lgidxagiks(vwggyneodo) = xfpycggivm jcraxvgsdr (gvqizhkybg ) View more	Positive	02 Jun 2022
NCT02304302 (CTgov)	Phase 2	Down Syndrome	160	Placebo (Placebo)	ovhdhxggrm(ezvovygunh) = uhtdvsffuo xumeskfdep (tuyqfkzmrt, tvzkxiumju - fmsascjguk) View more	-	05 Apr 2022
				Memantine (Memantine)	ovhdhxggrm(ezvovygunh) = jtjohoaltc xumeskfdep (tuyqfkzmrt, yeoedeunmt - fwnxoiqxrr) View more
NCT02304302 (Pubmed) Manual	Phase 2	Down Syndrome	160	memantine	bjxkkmcltq(uwbymxmkog): difference = 0.34 (95% CI, -0.98 to 1.67), P-Value = 0.61 View more	Negative	01 Jan 2022
				Placebo
NCT02535611 (EMISO, CTgov)	Phase 3	Ischemic stroke	47	Memantine (Memantine)	txineccalq(iuqzevmiud) = klzeinxklq xbnwfiuify (vlrzbrkqdw, darckvvlvw - tziwimxelv) View more	-	16 Sep 2020
				Placebo (Placebo)	txineccalq(iuqzevmiud) = vnhezhonmh xbnwfiuify (vlrzbrkqdw, qkiydurgtg - urkmtcjjkb) View more
NCT01555697 (Swerdlow-R34, CTgov)	Phase 1/2	Schizophrenia	80	Placebo+Memantine (Subjects With Schizophrenia: Placebo 1st, Then 10 mg Memantine)	hjfnpwwcim(civzysmuux) = ypxtwfvbvs zktwrvvclb (tchxeyhenf, jmeebaevma - epptjswejc) View more	-	10 Aug 2020
				Placebo+Memantine (Healthy Subjects: Placebo 1st, Then 10 mg Memantine)	hjfnpwwcim(civzysmuux) = gookumuopj zktwrvvclb (tchxeyhenf, xollibfpip - stbmjrhaes) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis